ticker
Login
business news
Politics And Regulation
Markets
The Economy
Editor's Pick
trading and investing
Stocks
ETFs
Fixed Income
Earnings
Currencies
Commodities
Options
Taxes
Personal Finance
How To Trade
How To Invest
sectors
Biotech/pharma
Consumer
Energy
Financial
Global Markets
Media
Precious Metals
Real Estate
Technology
Transportation
special features
Wall Of Worry
Random Thoughts
Sports Business
Minyanville Press
Video
Hoofy & Boo
Radio
MV PREMIUM
subscriptions
Launch Buzz And Banter
Buzz And Banter
Elliott Wave Insider
Tchir's Fixed Income Report
Cooper's Market Report
Techstrat Report
Optionsmith
The Stock Playbook
Ad Free Minyanville
Minyanville Book Store
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Seattle Genetics Inc /wa
(NQ:
SGEN
)
32.20
USD
+0.22 (+0.69%)
Official Closing Price
/ Updated:
4:00 PM EDT, Jun 18, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
0
Open
31.94
Bid (Size)
32.19 (800)
Ask (Size)
32.20 (5700)
Prev. Close
31.98
Today's Range
31.55 - 32.55
52wk Range
21.05 - 39.00
Shares Outstanding
121,265,608
Dividend Yield
N/A
Featured News
More News
Immunotherapy: Four Companies on the Verge of Cancer-Treatment Breakthroughs
June 17, 2013
Immunotherapy is a promising cancer-treatment program, and these companies are finding ways to treat aggressive forms of the deadly disease.
Read More
category
SGEN
,
CLDX
from
Minyanville Headlines
Celgene, Pharmacyclics, Ariad Pharmaceuticals, ImmunoGen, Array BioPharma Get Boost From Medical Conference
December 11, 2012
MINYANVILLE ORIGINAL Stocks for several drug makers are rising Tuesday following study results showing their therapies may be effective in treating different forms of blood diseases. The stocks some of...
Read More
from
Minyanville Headlines
Featured News
Read More
Celgene and More Big Movers in Healthcare on December 10, 2012
December 10, 2012
from
Investopedia Advisor Commentary
Seattle Genetics' Cancer Drug Highlighted at Medical Meeting
December 06, 2012
from
Minyanville Headlines
Celgene, NPS Pharmaceuticals, Amarin, J&J, Medivation Among Stocks to Watch in December
November 30, 2012
from
Minyanville Headlines
HCA and Other Healthcare Stocks Making Big Moves on November 8, 2012
November 08, 2012
from
Investopedia Advisor Commentary
Intuitive Surgical and More Big Movers in Healthcare on October 16, 2012
October 16, 2012
from
Investopedia Advisor Commentary
Zimmer and More Big Movers in Healthcare on September 7, 2012
September 07, 2012
from
Investopedia Advisor Commentary
More News
Read More
NASDAQ Announces Changes to Q-50 Index
June 17, 2013
from
StreetInsider.com News Articles
Quarterly Changes to the NASDAQ Q-50 Index
June 14, 2013
from
GlobeNewswire News Releases
Critical Alerts For International Business Machines, Du Pont, Juniper Networks, Sysco, and Seattle Genetics Released By InvestorsObserver
June 11, 2013
from
PR Newswire
Bearish Moving Average Cross by Seattle Genetics (SGEN)
June 10, 2013
from
Comtex SmarTrend® News Briefs
UPDATE: Seattle Genetics Announces Initiation of Phase 1/2 Trial of ADCETRIS (Brentuximab Vedotin) in Combination with Bendamustine for Hodgkin Lymphoma Patients after Initial Relapse
June 10, 2013
category
SGEN
,
Benzinga
,
News
, and 1 more.
from
Latest Articles from Benzinga.com
Seattle Genetics (SGEN) Initiates ADCETRIS Phase 1/2
June 10, 2013
from
StreetInsider.com News Articles
Seattle Genetics Announces Initiation of Phase 1/2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Bendamustine for Hodgkin Lymphoma Patients after Initial Relapse
June 10, 2013
from
Business Wire News Releases
Collaborations, Clinical Development Programs, FDA Approvals, New Treatments and Attractive Product Portfolios - Research Report on Medivation, Acadia, Santarus, Seattle Genetics, and PDL BioPharma
June 10, 2013
from
PR Newswire
Seattle Genetics Highlights ADCETRIS Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate Collaborator Data at ASCO
June 02, 2013
category
SGEN
,
Contracts
,
Management
, and 4 more.
from
Latest Articles from Benzinga.com
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting
June 02, 2013
from
Business Wire News Releases
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here
Stay Connected
WHAT'S POPULAR IN THE VILLE
1
The QE Carry Trade Is Imploding Right Under Everyone's Noses
Vince Foster
2
Immunotherapy: Four Companies on the Verge of Cancer-Treatment Breakthroughs
TM Meyer
3
Why Apple Inc. Can't Be Forgiven for iOS 7
Mike Schuster
4
What Now, Mr. Bernanke? Traders Position Into the FOMC Rate Decision
Todd Harrison
5
In Insider Trading, Phillip Frost Increases Stake in Opko Health Inc. and Larry Page Sells Shares of Google Inc
Jonathan Moreland
See All Articles
»